Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01047644 · ClinicalTrials.gov registry record · Phase 2
Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer.
A Phase 2 study of Complication of Catheter, sponsored by University of Louisville.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT01047644: Completed Phase 2 study of Complication of Catheter, sponsored by University of Louisville.
NCT01047644 is a Phase 2 study of Complication of Catheter that has completed, run by University of Louisville. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01047644, a Phase 2 study of Complication of Catheter, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of port (PAC) flushes every 3 months rather than every four to six weeks. It is routine practice to flush ports every four to six weeks, according to the manufacturer's recommendations, using salt solution followed heparin if needed. This study examines the effectiveness of port flushes at an alternative interval of 3 months, reducing the number of visits to the health-care provider.
Primary Outcome
The short-term endpoint is time to port complication (EFP- event free port-complication). The long term end point will be time to port failure requiring removal of the port (OAP - overal port failure) and will be used to determine the efficacy of port flushes every 3 months.
Conditions Studied
Interventions
- OTHER Reduced port-flush schedule
Study Locations (1)
Kentucky
- James Graham Brown Cancer Center - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2009-03 |
| Est. Completion | 2017-01 |
| Phase | Phase 2 |
What the finished NCT01047644 record still lists
NCT01047644 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Complication of Catheter appearing as the primary indexed condition, and to 1 intervention - of which Reduced port-flush schedule is the first listed.
NCT01047644 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT01047644 about?
NCT01047644 is a clinical study titled "Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer.". The purpose of this study is to evaluate the safety and effectiveness of port (PAC) flushes every 3 months rather than every four to six weeks. It is routine practice to flush ports every four to six weeks, according to the manufacturer's recommendations, using salt solution followed heparin if nee...
What is the current status of trial NCT01047644?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2009-03. Estimated completion is 2017-01.
What conditions does trial NCT01047644 study?
This clinical trial studies the following conditions: Complication of Catheter.
What interventions are being tested in trial NCT01047644?
The interventions under investigation include: Reduced port-flush schedule (OTHER).
Who is sponsoring clinical trial NCT01047644?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01047644 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01047644's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia